본문 바로가기
KERD
논문KCI 등재

The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls

Sung Won Lee|Hae Lim Lee
대한간학회 (The korean Association for the Study of the Liver)|2022.04|Clinical and Molecular Hepatology|제28권 제2호|pp. 121-134|DOI 10.3350/cmh.2021.0239

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

PortalHypertensionLiver cirrhosisTransjugular intrahepatic portosystemic shuntPortal pressure

초록

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective interventional procedure to relieve portal hypertension, which is a main mechanism for the development of complications of liver cirrhosis (LC), such as variceal hemorrhage, ascites, and hepatorenal syndrome. However, the high incidence of adverse events after TIPS implementation limits its application in clinical practice. Esophageal variceal hemorrhage is one of the major indications for TIPS. Recently, preemptively performed TIPS has been recommended, as several studies have shown that TIPS significantly reduced mortality as well as rebleeding or failure to control bleeding in patients who are at high risk of treatment failure for bleeding control with endoscopic variceal ligation and vasoactive drugs. Meanwhile, recurrent ascites is another indication for TIPS with a proven survival benefit. TIPS may also be considered as an effective treatment for other LC complications, usually as an alternative therapy. Although there are concerns about the development of hepatic encephalopathy and hepatic dysfunction after TIPS implementation, careful patient selection using prognostic scores can lead to excellent outcomes. Assessments of cardiac and renal function prior to TIPS may also be considered to improve patient prognosis.

Abstract

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective interventional procedure to relieve portal hypertension, which is a main mechanism for the development of complications of liver cirrhosis (LC), such as variceal hemorrhage, ascites, and hepatorenal syndrome. However, the high incidence of adverse events after TIPS implementation limits its application in clinical practice. Esophageal variceal hemorrhage is one of the major indications for TIPS. Recently, preemptively performed TIPS has been recommended, as several studies have shown that TIPS significantly reduced mortality as well as rebleeding or failure to control bleeding in patients who are at high risk of treatment failure for bleeding control with endoscopic variceal ligation and vasoactive drugs. Meanwhile, recurrent ascites is another indication for TIPS with a proven survival benefit. TIPS may also be considered as an effective treatment for other LC complications, usually as an alternative therapy. Although there are concerns about the development of hepatic encephalopathy and hepatic dysfunction after TIPS implementation, careful patient selection using prognostic scores can lead to excellent outcomes. Assessments of cardiac and renal function prior to TIPS may also be considered to improve patient prognosis.

참고문헌 (88)

  1. Trebicka J, "Emergency TIPS in a Child-Pugh B patient : when does the window of opportunity open and close?", J Hepatol, 66, pp.442~450 (2017)
  2. Rössle M, "The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding", N Engl J Med, 330, pp.165~171 (1994)
  3. Casado M, "Clinical events after transjugular intrahepatic portosystemic shunt : correlation with hemodynamic findings", Gastroenterology, 114, pp.1296~1303 (1998)
  4. Bureau C, "Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS : results of a randomized study", Gastroenterology, 126, pp.469~475 (2004)
  5. Bosch J, "Small diameter shunts should lead to safe expansion of the use of TIPS", J Hepatol, 74, pp.230~234 (2021)
  6. Trebicka J, "Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival", Clin Gastroenterol Hepatol, 17, pp.2793~2799 (2019)
  7. Wang Q, "Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding", J Hepatol, 67, pp.508~516 (2017)
  8. Tripathi D, "Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension", Gut, 69, pp.1173~1192 (2020)
  9. Garcia-Tsao G, "Portal hypertensive bleeding in cirrhosis : risk stratification, diagnosis, and management : 2016 practice guidance by the American Association for the study of liver diseases", Hepatology, 65, pp.310~335 (2017)
  10. LaBerge JM, "Histopathologic study of stenotic and occluded transjugular intrahepatic portosystemic shunts", J Vasc Interv Radiol, 4, pp.779~786 (1993)
  11. Saxon RR, "Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts : comparative histopathologic analysis in humans and swine", J Vasc Interv Radiol, 7, pp.487~497 (1996)
  12. Yingmei Tang, "Use of concomitant variceal embolization and prophylactic antiplatelet", anticoagulative in transjugular intrahepatic portosystemic shunting, 2017, pp.96(49), e8678~[DOI]
  13. Christian J. Steib, "Transjugular intrahepatic portosystemic shunt for patients with liver cirrhosis: survey evaluating indications, standardization of procedures and anticoagulation in 43 German hospitals", European Journal of Gastroenterology & Hepatology, 32(9), pp.1179~1185 (2019), Ovid Technologies (Wolters Kluwer Health)[DOI]
  14. Thomas D. Boyer, "The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009", Hepatology, 51(1), pp.306~306 (2009), Ovid Technologies (Wolters Kluwer Health)[DOI]
  15. García-Pagán JC, "Early use of TIPS in patients with cirrhosis and variceal bleeding", N Engl J Med, 362, pp.2370~2379 (2010)
  16. European Association for the Study of the Liver, "EASL clinical practice guidelines for the management of patients with decompensated cirrhosis", J Hepatol, 69, pp.406~460 (2018)
  17. Roberto de Franchis, "Expanding consensus in portal hypertension", Journal of Hepatology, 63(3), pp.743~752 (2015), Elsevier BV[DOI]
  18. Monescillo A, "Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding", Hepatology, 40, pp.793~801 (2004)
  19. Lv Y, "Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis : a randomised controlled trial", Lancet Gastroenterol Hepatol, 4, pp.587~598 (2019)
  20. The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications", Clinical and Molecular Hepatology, 26(2), pp.83~127 (2020), 대한간학회[DOI]
  21. Rudler M, "Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding, without improving survival", Aliment Pharmacol Ther, 40, pp.1074~1080 (2014)
  22. Garcia-Pagán JC, "Use of early-TIPS for high-risk variceal bleeding : results of a post-RCT surveillance study", J Hepatol, 58, pp.45~50 (2013)
  23. Augustin S, "Effectiveness of combined pharmacologic and ligation therapy in high-risk patients with acute esophageal variceal bleeding", Am J Gastroenterol, 106, pp.1787~1795 (2011)
  24. Nicoară-Farcău O, "Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding : a metaanalysis of individual patient data", Gastroenterology, 160, pp.193~205 (2021)
  25. Halabi SA, "Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients : a meta-analysis of randomized controlled trials", J Gastroenterol Hepatol, 31, pp.1519~1526 (2016)
  26. Holster IL, "Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding", Hepatology, 63, pp.581~589 (2016)
  27. Sauerbruch T, "Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy", Gastroenterology, 149, pp.660~668 (2015)
  28. Escorsell A, "TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis : a randomized controlled trial", Hepatology, 35, pp.385~392 (2002)
  29. Lo GH, "A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding", Endoscopy, 39, pp.679~685 (2007)
  30. Luo X, "Endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration for prevention of gastric variceal bleeding : a randomized controlled trial", Hepatology, 74, pp.2074~2084 (2021)
  31. Wang YB, "Balloon-occluded retrograde transvenous obliteration versus transjugular intrahepatic portosystemic shunt for treatment of gastric varices due to portal hypertension : a meta-analysis", J Gastroenterol Hepatol, 31, pp.727~733 (2016)
  32. Park JK, "Balloon-occluded retrograde transvenous obliteration(BRTO)for treatment of gastric varices : review and meta-analysis", Dig Dis Sci, 60, pp.1543~1553 (2015)
  33. Rössle M, "A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites", N Engl J Med, 342, pp.1701~1707 (2000)
  34. Ginès P, "Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis", Gastroenterology, 123, pp.1839~1847 (2002)
  35. Sanyal AJ, "The North American study for the treatment of refractory ascites", Gastroenterology, 124, pp.634~641 (2003)
  36. Salerno F, "Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites", Hepatology, 40, pp.629~635 (2004)
  37. Narahara Y, "Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function : a prospective randomized trial", J Gastroenterol, 46, pp.78~85 (2011)
  38. Bureau C, "Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites", Gastroenterology, 152, pp.157~163 (2017)
  39. Benmassaoud A, "Sarcopenia does not worsen survival in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt for refractory ascites", Am J Gastroenterol, 115, pp.1911~1914 (2020)
  40. Shen NT, "Cost effectiveness of early insertion of transjugular intrahepatic portosystemic shunts for recurrent ascites", Clin Gastroenterol Hepatol, 16, pp.1503~1510 (2018)
  41. Piecha F, "Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival", JHEP Rep, 1, pp.90~98 (2019)
  42. Surani SR, "Pulmonary complications of hepatic diseases", World J Gastroenterol, 22, pp.6008~6015 (2016)
  43. Raevens S, "Pulmonary abnormalities in liver disease : relevance to transplantation and outcome", Hepatology, 74, pp.1674~1686 (2021)
  44. Hou F, "Effectiveness and safety of pleurodesis for hepatic hydrothorax : a systematic review and meta-analysis", Dig Dis Sci, 61, pp.3321~3334 (2016)
  45. Gordon FD, "The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt", Hepatology, 25, pp.1366~1369 (1997)
  46. Jeffries MA, "Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax", Liver Transpl Surg, 4, pp.416~423 (1998)
  47. Siegerstetter V, "Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt : long-term results in 40 patients", Eur J Gastroenterol Hepatol, 13, pp.529~534 (2001)
  48. Spencer EB, "Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax", J Vasc Interv Radiol, 13, pp.385~390 (2002)
  49. Wilputte JY, "The outcome after transjugular intrahepatic portosystemic shunt(TIPS)for hepatic hydrothorax is closely related to liver dysfunction : a longterm study in 28 patients", Acta Gastroenterol Belg, 70, pp.6~10 (2007)
  50. Dhanasekaran R, "Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis", Am J Gastroenterol, 105, pp.635~641 (2010)
  51. Jindal A, "Efficacy and safety of transjugular intrahepatic portosystemic shunt in difficult-to-manage hydrothorax in cirrhosis", Liver Int, 39, pp.2164~2173 (2019)
  52. Saab S, "Practical tips on TIPS : when and when not to request it", Am J Gastroenterol, 115, pp.797~800 (2020)
  53. Qiu B, "Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension", World J Gastroenterol, 21, pp.12439~12447 (2015)
  54. Yan H, "Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites", Transl Oncol, 13, pp.100864~ (2020)
  55. Fan W, "Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS", Eur Radiol, 31, pp.8291~8301 (2021)
  56. Guevara M, "Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome : effects on renal function and vasoactive systems", Hepatology, 28, pp.416~422 (1998)
  57. Brensing KA, "Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome : a phase II study", Gut, 47, pp.288~295 (2000)
  58. Charilaou P, "Inpatient mortality benefit with transjugular intrahepatic portosystemic shunt for hospitalized hepatorenal syndrome patients", Dig Dis Sci, 65, pp.3378~3388 (2020)
  59. European Association for the Study of the Liver, "EASL clinical practice guidelines : vascular diseases of the liver", J Hepatol, 64, pp.179~202 (2016)
  60. Chen H, "Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction", J Gastroenterol Hepatol, 35, pp.1049~1056 (2020)
  61. Lv Y, "TIPSS for variceal bleeding in patients with idiopathic non-cirrhotic portal hypertension : comparison with patients who have cirrhosis", Aliment Pharmacol Ther, 49, pp.926~939 (2019)
  62. Sarwar A, "Hospital volume and mortality after transjugular intrahepatic portosystemic shunt creation in the United States", Hepatology, 67, pp.690~699 (2018)
  63. Martin Depaire, "Futility criteria for preemptive TIPS in patients with cirrhosis and variceal bleeding are still missing in most severe patients!", Journal of Hepatology, 74(4), pp.997~999 (2021), Elsevier BV[DOI]
  64. Trebicka J, "Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS", J Hepatol, 73, pp.1082~1091 (2020)
  65. Luca A, "Early liver failure after transjugular intrahepatic portosystemic shunt in patients with cirrhosis with model for end-stage liver disease score of 12 or less : incidence, outcome, and prognostic factors", Radiology, 280, pp.622~629 (2016)
  66. Berlioux P, "Pre-transjugular intrahepatic portosystemic shunts(TIPS)prediction of post-TIPS overt hepatic encephalopathy : the critical flicker frequency is more accurate than psychometric tests", Hepatology, 59, pp.622~629 (2014)
  67. Ankur Jindal, "Sarcopenia: Ammonia metabolism and hepatic encephalopathy", Clinical and Molecular Hepatology, 25(3), pp.270~279 (2019), 대한간학회
  68. Nardelli S, "Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement", Clin Gastroenterol Hepatol, 15, pp.934~936 (2017)
  69. Gioia S, "The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS", Liver Int, 39, pp.871~877 (2019)
  70. Riggio O, "Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt : a randomized controlled study", J Hepatol, 42, pp.674~679 (2005)
  71. Vilstrup H, "Hepatic encephalopathy in chronic liver disease : 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver", Hepatology, 60, pp.715~735 (2014)
  72. Bureau C, "The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt : a randomized controlled trial", Ann Intern Med, 174, pp.633~640 (2021)
  73. Razpotnik M, "The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria", Liver Int, 41, pp.1058~1069 (2021)
  74. Chahal D, "Review article : comprehensive analysis of cirrhotic cardiomyopathy", Aliment Pharmacol Ther, 53, pp.985~998 (2021)
  75. Armstrong MJ, "Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stent-shunt in patients with cirrhosis", Aliment Pharmacol Ther, 49, pp.797~806 (2019)
  76. Billey C, "A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt : the toulouse algorithm", Hepatology, 70, pp.1928~1941 (2019)
  77. Wong F, "Transjugular intrahepatic portosystemic stent shunt : effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites", Ann Intern Med, 122, pp.816~822 (1995)
  78. Wong F, "The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt", Gastroenterology, 112, pp.899~907 (1997)
  79. Allegretti AS, "Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis : a matched cohort analysis", Am J Kidney Dis, 68, pp.381~391 (2016)
  80. Anderson CL, "Effect of transjugular intrahepatic portosystemic shunt placement on renal function : a 7-year, single-center experience", J Vasc Interv Radiol, 21, pp.1370~1376 (2010)
  81. Ge J, "Nonalcoholic fatty liver disease and diabetes mellitus are associated with post-transjugular intrahepatic portosystemic shunt renal dysfunction : an advancing liver therapeutic approaches group study", Liver Transpl, 27, pp.329~340 (2021)
  82. Somberg KA, "Transjugular intrahepatic portosystemic shunts for refractory ascites : assessment of clinical and hormonal response and renal function", Hepatology, 21, pp.709~716 (1995)
  83. Riggio O, "Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts", Am J Gastroenterol, 103, pp.2738~2746 (2008)
  84. Malinchoc M, "A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts", Hepatology, 31, pp.864~871 (2000)
  85. Guy J, "New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt", Clin Gastroenterol Hepatol, 7, pp.1236~1240 (2009)
  86. Bureau C, "Serum bilirubin and platelet count : a simple predictive model for survival in patients with refractory ascites treated by TIPS", J Hepatol, 54, pp.901~907 (2011)
  87. Bettinger D, "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival", J Hepatol, 74, pp.1362~1372 (2021)
  88. The Korean Association for the Study of the Liver, "2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C", Clinical and Molecular Hepatology, 24(3), pp.230~277 (2018), 대한간학회

관련 논문AI추천

Transjugular intrahepatic portosystemic shunt creation for portal hypertension in patients with hepatocellular carcinoma: A systematic reviewHe Zhao, Jiaywei Tsauo, Jinggui Li, Tao Gong, Xiao Li소화기인터벤션의학회 · International Journal of Gastrointestinal Intervention2018 · 제7권 제3호Clinical outcomes of transjugular intrahepatic portosystemic shunt for portal hypertension: Korean multicenter real-practice data김도영, 김문영, 김순선, 김영석, 김윤준, 김형기, 박성재, 박수영, 백순구, 심재준, 엄순호, 우현영, 이재명, 전대원, 정영걸, 정우진, 최문석대한간학회 · Clinical and Molecular Hepatology2014 · 제20권 제1호A review of recent experience with transjugular intrahepatic portosystemic shunt creation using intravascular ultrasoundEdward Wolfgang Lee, Steven D. Kao소화기인터벤션의학회 · International Journal of Gastrointestinal Intervention2018 · 제7권 제1호Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shuntChaoxue Zhang, Dongmei Zhao, Guobing Zhang, Jiabin Li, Mingquan Wang대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제2호Transjugular intrahepatic portosystemic shunt trends in China: A brief reviewXiao JiangQiang, ZhuGe YuZheng소화기인터벤션의학회 · International Journal of Gastrointestinal Intervention2018 · 제7권 제1호Portal and hepatic vein thrombosis after transjugular intrahepatic portosystemic shunt: Incidence in follow-up imaging and clinical implicationsAdam Khalil, Barrett P. O’Donnell, Eric Reuben Smith, Jorge Lopera, Mario Vela, Osamah Al-Bayati, Partha Mandal, Serena Jen소화기인터벤션의학회 · International Journal of Gastrointestinal Intervention2022 · 제11권 제1호

이 간행물의 다른 논문 (18건)

Approaches to quantifying hepatitis B virus covalently closed circular DNAThomas Tu, Henrik Zhangpp. 135-149MAFLD enhances clinical practice for liver disease in the Asia-Pacific regionTakuji Torimura, Takumi Kawaguchi, Mohammed Eslam, Tsubasa Tsutsumi, Dan Nakano, Jacob Georgepp. 150-163Cost-effectiveness of chronic hepatitis C screening and treatment김도영, 이한길, 이혜원, 김범경, Jae Young Jang, Young Changpp. 164-173Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still openBo Hyun Kimpp. 174-176Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosisTakuji Torimura, Takumi Kawaguchipp. 177-180
원문 보기